Global Tasimelteon Market 2026 by Company, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Tasimelteon market size was valued at US$ 109 million in 2025 and is forecast to a readjusted size of US$ 121 million by 2032 with a CAGR of 1.4% during review period.
Tasimelteon is a selective melatonin MT1 and MT2 receptor agonist used primarily for Non-24-Hour Sleep-Wake Disorder in adults and nighttime sleep disturbances associated with Smith-Magenis syndrome. It improves sleep timing and continuity through circadian rhythm regulation rather than conventional central nervous system sedation. Commercial dosage forms mainly include 20 mg capsules and a 4 mg/mL oral suspension. Upstream inputs include tasimelteon active pharmaceutical ingredient, capsule shells, fillers, suspending agents, thickeners, sweeteners, buffers, pharmaceutical bottles, and dosing devices. Downstream customers mainly include sleep medicine centers, neurology departments, genetic disorder specialists, pediatric departments, specialty pharmacies, hospital pharmacies, and regulated pharmaceutical distributors. The treated patient population is relatively small and requires specialist diagnosis, and the market consists mainly of the originator brand and a limited number of U.S. generic manufacturers, with an overall gross margin generally ranging from approximately 68% to 85%.
From the current market perspective, tasimelteon is primarily used for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis syndrome. The addressable patient population is relatively limited, giving the market clear rare-disease and specialty-drug characteristics. Commercial demand is concentrated mainly in the United States, where the originator product retains advantages through indication coverage, a pediatric oral suspension, specialty pharmacy access, and patient support services, while the adult capsule segment has entered generic competition. Diagnosis depends heavily on sleep medicine, neurology, and genetic disorder specialists, resulting in a highly concentrated prescribing and distribution structure.
Looking ahead, the adult capsule segment will remain exposed to generic substitution and pricing pressure, while growth opportunities for the originator will increasingly depend on pediatric formulations, broader treatment coverage in Smith-Magenis syndrome, and development in additional circadian rhythm disorders. Oral suspension, weight-based dosing, and adherence support are expected to remain important areas of differentiation. Wider use of circadian rhythm monitoring, digital follow-up tools, and telemedicine may also improve patient identification, treatment assessment, and long-term therapy management.
Key market drivers include improving awareness of Non-24 among totally blind individuals, expansion of specialist sleep medicine services, and better diagnosis of rare genetic disorders. Patients with Smith-Magenis syndrome often require long-term management of sleep disturbances, and tasimelteon's defined receptor target and circadian rhythm mechanism support its role in structured specialist treatment. In addition, tasimelteon is not a conventional controlled sedative-hypnotic and carries a comparatively lower burden related to dependence and abuse management, which supports continued use under specialist supervision.
The main constraints include a narrow eligible patient population and a complex process of patient identification, diagnosis, and referral. High branded treatment costs, insurance access requirements, prior authorization, and patient affordability can directly limit treatment uptake. As generic capsules gain share, prescription volume may continue to increase, but average selling prices and originator revenue are likely to remain under pressure. Lower-cost alternatives such as melatonin, the absence of immediate sedative effects, and the need for consistent long-term dosing may also influence treatment selection and adherence.
This report is a detailed and comprehensive analysis for global Tasimelteon market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tasimelteon market size and forecasts, in consumption value ($ Million), 2021-2032
Global Tasimelteon market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Tasimelteon market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Tasimelteon market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tasimelteon
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tasimelteon market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Vanda Pharmaceuticals, Teva Pharmaceutical Industries, Apotex, MSN Laboratories, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Tasimelteon market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Capsules
Oral Suspension
Market segment by Product Status
Originator Drug
Generic Drugs
Market segment by Patient Group
Adult Patients
Pediatric Patients
Market segment by Application
Hospital
Clinic
Other
Market segment by players, this report covers
Vanda Pharmaceuticals
Teva Pharmaceutical Industries
Apotex
MSN Laboratories
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Tasimelteon product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Tasimelteon, with revenue, gross margin, and global market share of Tasimelteon from 2021 to 2026.
Chapter 3, the Tasimelteon competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Tasimelteon market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Tasimelteon.
Chapter 13, to describe Tasimelteon research findings and conclusion.